We investigated the role of six genetic variants in the MTHFR and 5-methylenetetrahydrofolate-homocysteine methyltransferase reductase (MTRR) genes on the clinical outcome in 273 colorectal cancer patients who were administered a 5-FU based regimen as first-line post-operative therapy.